Form 4: Procept BioRobotics Executive Sells Shares and Exercises Options

Alaleh Nouri, an executive at Procept BioRobotics, executed multiple transactions involving the sale of common stock and the exercise of stock options on December 4, 2024.

Summary

• Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics, engaged in several transactions on December 4, 2024.
• These transactions included the exercise of stock options to acquire 28,092 shares of common stock at prices of $7.27, $34.99, and $37.02 per share.
• Nouri also sold 27,092 shares of common stock at weighted average prices ranging from $96.12 to $97.90 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 3, 2024.
• Following these transactions, Nouri's direct holdings of common stock decreased to 52,472 shares, while also holding options for 49,878 shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan. While the sales might cause some concern, the use of a 10b5-1 plan mitigates the negative sentiment. The sentiment is neutral.

Risks

• Executive stock sales could be perceived negatively by the market, potentially impacting the stock price.
• The use of a 10b5-1 trading plan indicates pre-planned sales, which may suggest a lack of confidence in the company's short-term prospects, although this is not always the case.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are routinely disclosed through SEC filings. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the medical device sector like Procept BioRobotics.
• Companies such as Intuitive Surgical (ISRG) and Stryker (SYK) also have executives who utilize similar trading plans to manage their stock holdings.
• The reported sale prices are within the typical range for market transactions, and the exercise prices reflect the historical grant prices of the options.

Stakeholder Impact

• Shareholders may react to the executive's stock sales, potentially impacting the stock price.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

insider trading, stock options, share sales, Rule 10b5-1, executive compensation, Procept BioRobotics, PRCT